标题/作者	年份
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease M Eslam, SK Sarin, VWS Wong, JG Fan, T Kawaguchi, SH Ahn, ... Hepatology international 14, 889-919	2020
The complex link between NAFLD and type 2 diabetes mellitus—mechanisms and treatments G Targher, KE Corey, CD Byrne, M Roden Nature reviews Gastroenterology & hepatology 18 (9), 599-612	2021
Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial S Kahl, S Gancheva, K Straßburger, C Herder, J Machann, H Katsuyama, ... Diabetes care 43 (2), 298-305	2020
The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD) DM Tanase, EM Gosav, CF Costea, M Ciocoiu, CM Lacatusu, ... Journal of diabetes research 2020	2020
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management T Marjot, A Moolla, JF Cobbold, L Hodson, JW Tomlinson Endocrine reviews 41 (1), 66-117	2020
Гепатопротекторы СВ Оковитый, ВА Приходько, НН Безбородкина, БН Кудрявцев Общество с ограниченной ответственностью Издательская группа ГЭОТАР-Медиа	2022
Metabolic liver disease in diabetes–from mechanisms to clinical trials B Dewidar, S Kahl, K Pafili, M Roden Metabolism 111, 154299	2020
Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials A Mantovani, G Petracca, A Csermely, G Beatrice, G Targher Metabolites 11 (1), 22	2020
MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy YX Xian, JP Weng, F Xu Chinese medical journal 134 (01), 8-19	2021
NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment G Targher, KE Corey, CD Byrne Diabetes & metabolism 47 (2), 101215	2021
Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial H Taheri, M Malek, F Ismail-Beigi, F Zamani, M Sohrabi, M Reza Babaei, ... Advances in therapy 37, 4697-4708	2020
The race to bash NASH: emerging targets and drug development in a complex liver disease FA Romero, CT Jones, Y Xu, M Fenaux, RL Halcomb Journal of medicinal chemistry 63 (10), 5031-5073	2020
Providing diagnosis on diabetes using cloud computing environment to the people living in rural areas of India DS Rajput, SM Basha, Q Xin, TR Gadekallu, R Kaluri, K Lakshmanna, ... Journal of Ambient Intelligence and Humanized Computing, 1-12	2022
Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial H Chehrehgosha, MR Sohrabi, F Ismail-Beigi, M Malek, M Reza Babaei, ... Diabetes Therapy 12, 843-861	2021
Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes K Cusi Diabetes Care 43 (2), 275-279	2020
Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis J Lambrecht, LA van Grunsven, F Tacke Expert opinion on pharmacotherapy 21 (13), 1637-1649	2020
Renal physiology of glucose handling and therapeutic implications DZ Cherney, M Kanbay, JA Lovshin Nephrology Dialysis Transplantation 35 (Supplement_1), i3-i12	2020
Antidiabetic drugs and statins in nonalcoholic fatty liver disease S Kothari, H Dhami-Shah, SR Shah Journal of clinical and experimental hepatology 9 (6), 723-730	2019
Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD H Takahashi, T Kessoku, M Kawanaka, M Nonaka, H Hyogo, H Fujii, ... Hepatology communications 6 (1), 120-132	2022
Comparison of the effects of three kinds of glucose‐lowering drugs on non‐alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open‐label, three‐arm, active control study T Kinoshita, M Shimoda, K Nakashima, Y Fushimi, Y Hirata, A Tanabe, ... Journal of diabetes investigation 11 (6), 1612-1622	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。